The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Herthena-Lung02 data are an ASCO shocker.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.